{"entity":{"id":"nct06927687","kind":"trial","name":"Study of ZG005 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 2 trial of ZG005 for Injection in advanced solid tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, active and no longer recruiting.","summary":"Study of ZG005 in Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT06927687 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 50 participants enrolled, started 2025-06-13 and due to reach its primary completion in 2027-05. Interventions recorded: ZG005 for Injection.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06927687","url":"https://clinicaltrials.gov/study/NCT06927687"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["zelgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06927687","phase":"2","setting":"A Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of ZG005 in Patients With Advanced Solid Tumors","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","enrolled":50,"outcomes":[]},"route":"/trials/nct06927687/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"zelgen","kind":"company","name":"Suzhou Zelgen Biopharmaceuticals","route":"/companies/zelgen/"}]}}